Antiplatelet Drug Resistances and Ischemic Events
ADRIE
2 other identifiers
observational
771
1 country
1
Brief Summary
The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2006
CompletedFirst Submitted
Initial submission to the registry
July 13, 2007
CompletedFirst Posted
Study publicly available on registry
July 16, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedJanuary 31, 2014
January 1, 2014
4.3 years
July 13, 2007
January 30, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
MACE
adjudicating committee
prospective follow-up
Secondary Outcomes (1)
MACE in pre-specified sub-groups
prospective follow-up
Other Outcomes (1)
potential determinants of platelet reactivity
at inclusion
Eligibility Criteria
Documented symptomatic ischemic atherothrombotic disease
You may qualify if:
- Documented symptomatic ischemic atherothrombotic disease treated by aspirin, clopidogrel or both.
You may not qualify if:
- Known platelet disorder
- Chronic treatment by antiplatelet drugs other than aspirin or clopidogrel.
- Chronic anticoagulant treatment
- Chronic non steroid anti inflammatory drug treatment
- Active cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pierre Fontanalead
- Beziers Hospitalcollaborator
- University Hospital, Montpelliercollaborator
- Ministry of Health, Francecollaborator
- Swiss National Science Foundationcollaborator
Study Sites (1)
University Hospital Geneva; Beziers and Monpellier University Hospitals, France
Geneva - Beziers - Montpellier, France
Related Publications (2)
Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, Fontana P; Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation. 2012 Jun 26;125(25):3201-10. doi: 10.1161/CIRCULATIONAHA.111.085464. Epub 2012 May 21.
PMID: 22615340DERIVEDFontana P, James R, Barazer I, Berdague P, Schved JF, Rebsamen M, Vuilleumier N, Reny JL. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost. 2011 Aug;9(8):1664-6. doi: 10.1111/j.1538-7836.2011.04409.x. No abstract available.
PMID: 21692977DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Pierre Fontana, MD PhD
University Hospitals Geneva, Switzerland
- PRINCIPAL INVESTIGATOR
Jean-Luc Reny, MD PhD
Beziers Hospital, France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- PI
Study Record Dates
First Submitted
July 13, 2007
First Posted
July 16, 2007
Study Start
June 1, 2006
Primary Completion
September 1, 2010
Study Completion
September 1, 2010
Last Updated
January 31, 2014
Record last verified: 2014-01